Rankings
▼
Calendar
RCUS Q2 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
RCUS
Arcus Biosciences, Inc.
$2B
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$29M
+7.4% YoY
Gross Profit
$29M
100.0% margin
Operating Income
-$83M
-286.2% margin
Net Income
-$75M
-258.6% margin
EPS (Diluted)
$-1.02
QoQ Revenue Growth
+16.0%
Cash Flow
Operating Cash Flow
-$57M
Free Cash Flow
-$62M
Stock-Based Comp.
$18M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$654M
Stockholders' Equity
$566M
Cash & Equivalents
$230M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$29M
$27M
+7.4%
Gross Profit
$29M
$27M
+7.4%
Operating Income
-$83M
-$69M
-20.3%
Net Income
-$75M
-$67M
-11.9%
Revenue Segments
License and Development Services Revenue
$19M
66%
Other Collaboration Revenue
$10M
34%
← FY 2023
All Quarters
Q3 2023 →